Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P40306
UPID:
PSB10_HUMAN
Alternative names:
Low molecular mass protein 10; Macropain subunit MECl-1; Multicatalytic endopeptidase complex subunit MECl-1; Proteasome MECl-1; Proteasome subunit beta-2i
Alternative UPACC:
P40306; B2R5J4; Q5U098
Background:
Proteasome subunit beta type-10, also known as Low molecular mass protein 10 and several other names, plays a crucial role in the proteasome, a complex responsible for degrading unneeded or damaged proteins by proteolysis. This subunit is specifically involved in antigen processing, generating peptides that bind to class I molecules, essential for the immune response.
Therapeutic significance:
The protein is linked to Proteasome-associated autoinflammatory syndrome 5, a disorder marked by recurrent skin rashes, fever, and persistent hepatosplenomegaly. Understanding the role of Proteasome subunit beta type-10 could open doors to potential therapeutic strategies for this and related autoinflammatory conditions.